T he use of autograft bone to achieve a spinal fusion is the gold standard by which all other grafting materials are judged. Its dependable rate of incorporation leading to a successful spinal arthrodesis has been documented. 2 The potential benefits of using recombinant human bone morphogenetic protein-2 (rhBMP-2) over autograft or allograft bone are numerous. These may include decreased operating time, blood loss, donor site morbidity, 9 transmission of infection associated with use of allograft, 5 and rate of pseudarthrosis. 10 In addition, its unlimited quantity and immediate availability make it useful in certain pediatric spine applications, although its cost may be prohibitive in some settings. There are concerns regarding the routine and so-called off-label substitution or supplementation of autologous or allograft bone graft with rhBMP-2. The most significant concerns involve the possibility of bony overgrowth, interaction with exposed dura mater, cancer risk, systemic toxicity, local toxicity, immunogenicity, osteoclastic activation, and effects on distal organs. Object. Current national patterns as a function of patient-, hospital-, and procedure-related factors, and complication rates in the use of recombinant human bone morphogenetic protein-2 (rhBMP-2) as an adjunct to the practice of pediatric spine surgery have scarcely been investigated.
The issue of whether rhBMP-2 is an adequate substitute or supplement for bone graft in achieving a successful fusion is being studied thoroughly. Several clinical studies have documented favorable results by using adult lumbar spine and anterior cervical spine models. 6, 9 Although BMP has been used with some frequency in pediatric oral maxillofacial reconstructions 7, 8, [13] [14] [15] 18, 26, 56 and reported in the treatment of congenital pseudarthrosis of the tibia, 32, 46 there have been few reports of rhBMP-2 use 1, 4, 20, 36, 37, 40 in pediatric spine fusions. One recent study 31 of patients in the pediatric age group in the Nationwide Inpatient Sample database analyzed various factors associated with the use of BMP for specific diagnoses, including adolescent idiopathic scoliosis, Scheuermann kyphosis, congenital kyphosis, spondylolisthesis, and thoracolumbar fracture; procedures related to the occipitocervical and cervical spine were not included in this study.
The purpose of our study was to examine the nationwide practice patterns of occipitocervical, cervical, thoracic, lumbar, or lumbosacral spine fusion in which rhBMP-2 was used in pediatric patients by searching the Kids' Inpatient Database (KID). We suggest that patient-, hospital-, and procedure-related factors shape BMP use today.
Methods

Data Source
Data are from the 2009 KID developed by the Healthcare Cost and Utilization Project, sponsored by the Agency for Healthcare Research and Quality. 25 The 2009 KID contains discharge-level data from more than 3.4 million pediatric hospitalizations from 4121 nonfederal community hospitals in 44 states. The KID allows for more precise national and regional estimates for pediatric conditions, clinical outcomes, and hospital services, which are otherwise difficult to analyze given that children make up a relatively small proportion of hospital stays. It is important to note that because the data in KID are a composite of deidentified state-level information, our unit of analysis is a patient discharge and not a patient.
To obtain national estimates, patient records were provided with weights by using the American Hospital Association roster of nonfederal community hospitals as the standard. Hospital data were stratified by the following 6 characteristics: ownership/control, bed size, teaching status, rural/urban location, US region, and status as a freestanding children's hospital.
Patient Selection
We selected records associated with spinal fusion surgery for patients up to 20 years of age. These records were identified using discharge diagnosis codes defined by the International Classification of Diseases, Ninth Revision, Clinical Modifications (ICD-9-CM). The following ICD-9-CM procedure codes representing spinal fusion surgeries were used: (81.00-81.08, and 81. 30-81.39 ). In addition, procedures with ICD-9-CM (84.52) insertion of rhBMP-2 were identified. The unit of analysis in KID is a patient hospital discharge rather than a patient. Thus each hospitalization is tracked separately, without ability for outcomes follow-up over time.
Patient Characteristics
Patient characteristics obtained from the database include age (in years); sex; race (white, black, Hispanic, Asian or Pacific Islander, Native American, and other); in-hospital death; length of hospital stay ([LOS] in days); family income (by quartiles of median income in ZIP code); and primary payer (Medicaid, private, self-pay, or other).
Spine-related diagnoses were identified with the following ICD-9-CM codes for adolescent idiopathic scoliosis (737. 30 
Statistical Analysis
Descriptive statistics with weighted national estimates were conducted to evaluate the distribution of patient and hospital characteristics for those with or without rhBMP-2 use associated with their spinal fusion surgery. Patient and hospital characteristics across those with or without rhBMP-2 were compared with chi-square tests. Because KID is a sampled database, our results are reported as estimated values such as means and frequencies with 95% confidence intervals. These estimates represent national estimates for the associated year. Because of the sampling methodology, national medians cannot be obtained. Hence, continuous data are expressed as estimated means.
Standard errors were adjusted for stratification and clustering of the KID sampling design as described in the 2009 KID documentation published by the Agency for Healthcare Research and Quality. 25 Because the data in KID are a composite of deidentified state-level information, our unit of analysis is a patient discharge. To evaluate the effect of patient and hospital characteristics on rhBMP-2 use in pediatric patients undergoing spinal fusion surgery, univariate and multivariate logistic regression were used to calculate unadjusted and adjusted odds ratios (aORs) and 95% confidence intervals. Two-sided tests were used, with p values < 0.05 considered to be statistically significant. All statistical analyses were performed with Stata version 12 software (StataCorp).
Results
We identified 9538 discharge records associated with spinal fusion surgery in pediatric patients up to 20 years of age in 2009. Because the database is a weighted national sample, this represents an estimated 14,264 cases of spinal fusion surgery in the US. Nearly 11% of these cases involved intraoperative BMP use (10.8%, 95% CI 9.0%-12.6%).
Patient-Related Factors
Patient demographics are summarized in Table 1 . The majority of patients with spinal fusions were between the ages of 15 and 20 years (53.1%, 95% CI 51.2%-55.0%). Older age was a statistically significant predictor for BMP use in the multivariate logistic analysis (Table 2 ); 72.0% of patients in whom BMP was used were between the ages of 15 and 20 years compared with 50.8% in the non-BMP group. Sex and race were not significant predictors.
Overall, the majority of children with spinal fusions had private insurance (64.6%, 95% CI 61.9-67.2). Private insurance was also a significant predictor for BMP use (aOR 1.49, 95% CI 1.23-1.82, p < 0.001).
Preoperative diagnosis was a statistically significant predictor for BMP use. In the multivariate logistic regression, Scheuermann kyphosis (aOR 1.56, 95% CI 1.08-2.24, p < 0.017) and spondylolisthesis (aOR 1.93, 95% CI 1.46-2.55, p < 0.001) were associated with increased odds of BMP use. Patients with a cervical fracture or dislocation (aOR 0.57, 95% CI 0.41-0.81, p = 0.002), congenital scoliosis (aOR 0.54, 95% CI 0.35-0.81, p = 0.003), and idiopathic scoliosis (aOR 0.56, 95% CI 0.42-0.73, p < 0.001) were less likely to receive BMP.
Hospital-Related Factors
Hospital characteristics are summarized in Table 1 . Status as children's hospital was a significant predictor for BMP use in this population. Children's general/specialty hospitals had decreased odds of BMP use compared with nonchildren's hospitals (aOR 0.40, 95% CI 0.19-0.86, p = 0.019). Hospital bed size was not a significant predictor (Table 2) .
Region was also found to be a significant predictor, with the Midwest having increased odds of BMP use compared with the Northeast (aOR 2.49, 95% CI 1.27-4.89, p = 0.008). The South and West also appeared to have increased BMP use compared with the Northeast, but neither of these regions reached statistical significance (p = 0.066, Table 2 ).
Procedure-Related Factors
Procedure-related factors were found to be significant predictors for BMP use. Both posterior occipitocervical and anterior lumbar approaches had increased odds of BMP use compared with posterior lumbar approaches (aOR 1.86, 95% CI 1.14-3.04, p = 0.013 and aOR 1.73, 95% CI 1.32-2.26, p < 0.001, respectively). An anterior cervical approach was found to have lower odds of BMP use compared with a posterior lumbar approach (aOR 0.25, 95% CI 0.15-0.41, p < 0.001).
Length of the spinal fusion was also a significant predictor. Both short-and midsegment fusions were more likely to involve BMP use compared with long-segment fusions (aOR 1.42, 95% CI 1.07-1.89, p = 0.016 and aOR 1.44, 95% CI 1.12-1.87, p = 0.005, respectively). In addition, patients undergoing redo surgery for failed fusion were more likely to receive BMP (aOR 2.20, 95% CI 1.67-2.90, p < 0.001) ( Table 2) .
Acute Complications
Complications are summarized in Table 3 . Overall, rates of DVT, meningitis, wound infection, and wound dehiscence remained low (< 2%). Patients with intraoperative BMP use had lower rates of blood transfusion (15.5% vs 26.2%, p < 0.001).
The LOS, number of procedures and comorbidities, and total hospital costs are summarized in Table 4 . There was a significant difference in the average cost of hospitalization between the BMP and non-BMP groups ($58,653.70 vs $53,420.50; p < 0.001). There were no significant differences in LOS.
Discussion
This BMP-based fusion technology has experienced a rapid increase in use in all types of routine spine fusion procedures, including anterior cervical discectomy and fusion, posterolateral lumbar and cervical fusions, posterior and transforaminal lumbar interbody fusions, and pediatric spine fusions. 17 Cahill et al. 11 noted that the nationwide use of BMP increased from 0.69% of all fusions in 2002 to 24.89% of all fusions in 2006, confirming the widespread application of this technology and its routine use in spine fusion surgery. Similarly, Jain et al. 31 showed that the nationwide use of BMP in pediatric thoracic, lumbar, and sacral spine fusion surgery increased 3.4-fold from 2003 to 2009 (a 16% annual increase during the study period). We showed that a significant number of pediatric spinal fusion surgeries (> 10%) used BMP in 2009.
The osteoinductive role of rhBMP-2 is multifaceted; it acts as a chemotactic agent, a growth factor, and a differentiation factor. 54 The FDA has approved rhBMP-2 as the first complete bone graft substitute for anterior interbody fusions of the adult lumbar spine. 58 In clinical trials, investigators have demonstrated the usefulness of Although the FDA has only approved the use of rh-BMP-2-soaked absorbable collagen sponges for use in adult anterior lumbar interbody fusion, off-label applications have been reported.
12,37 These off-label uses of rh-BMP-2 have been sparsely reported in the pediatric neurosurgical and orthopedic literature. 1, 4, 20, 31, 36, 37, 40 We showed that the odds of BMP use in pediatric spine surgery increased with posterior occipitocervical and anterior lumbar fusion surgeries, whereas they decreased with anterior cervical approaches. This pattern probably reflects the recognition of an increased incidence of dysphagia with use of BMP in anterior cervical fusion surgery. 51 
Advantages of rhBMP-2
Biomechanically, the rhBMP-2-generated fusion mass is superior at 3 months compared with that generated by autograft. 47, 48 Findings have shown the fusion mass to be more mature, with more advanced remodeling and marrow formation, than that generated by autograft alone. Bone healing and remodeling may take up to 12-24 months. 16 Our study demonstrates that BMP, due to its potential to increase fusion rate, is more likely to be used to salvage previously failed bony fusion.
Another advantage of rhBMP-2 is its potential role in promoting fusion in very young children (even though our analysis demonstrates older age as a factor for increased use of BMP). These patients, especially those undergoing occipitocervical fusion, have a very limited amount of bone available for local autograft; meanwhile, autograft harvest at remote donor sites such as the ribs or iliac crest carries added morbidity. In fact, our review of pediatric spinal fusions showed that BMP use and the application of autograft were uncoupled. The literature shows that in these cases the ability to promote fusion by adding rh-BMP-2 is advantageous. Moreover, we found that the complication rate in the BMP group versus the non-BMP group was low, including a statistically significant reduction in rates of blood transfusion and postoperative hematoma formation. However, there was no difference in LOS between the two cohorts.
Cancer Risk
Although an analysis of the possible long-term consequences of BMP in the pediatric age group is beyond the scope of our present study, we would be remiss if our discussion did not include at least a brief review of its cancer risk and other lasting safety concerns. Both BMPs and BMP receptors have been isolated from human tumors. However, in vitro studies suggest that rhBMP-2 has an antiproliferative effect on human tumor colony-forming units taken from breast, ovarian, lung, and prostate cancers, and on embryonal cell carcinoma and cerebellar neuroectodermal tumor cell lines. 28, 29, 53, 55 Detailed data from the preclinical safety studies of manufacturers failed to demonstrate any proliferative effects of rhBMP-2 on * NR = not reported; QRTL = quartile; + = no report for < 11 cases, per KID reporting rules. † In these categories, calculated total and added total differ by 1 due to rounding.
human osteosarcoma, prostate, breast, tongue, and lung carcinoma cell lines; on the contrary, there was an inhibitory effect in all cases. In fact, rhBMP-2 was found to have no mutagenic activity. 44 Recent systemic reviews and meta-analyses of the literature 17, 21, 50 suggest that the cancer risk associated with rhBMP-2 may be dose dependent. The cancer risk was similar in the lower doses (4.2-4.8 mg) of rhBMP-2 (0.7%) and the control groups (0.7% and 0.9%). However, the cancer risk was 3.8% in the higher-dose (40 mg) rhBMP-2 study. 19 A recent large retrospective database study by Lad et al. 34 looked at high-dose BMP and its relationship to cancer. The authors looked at BMP exposure and cancer risk at a national level by performing a retrospective cross-sectional study in which a large MarketScan database with at least a 24-month postoperative follow-up was used (mean postoperative follow-up between 49.7 and 55.6 months). Analysis showed a significant increase (31%) in benign tumors but not malignancies. 34 Moreover, there was a significantly higher number of benign tumors of the spinal meninges in the BMP group.
Other Safety Concerns
There have been anecdotal reports of complications associated with rhBMP-2 use, with compressive bone formation adjacent to neural structures. 12 This is particularly relevant after decompressive laminectomy or foraminotomy, in which raw bone surfaces are exposed. 44 There is evidence to suggest that rhBMP-2 may lead to laminar reconstitution and neuroforaminal stenosis if it is implanted directly into the laminectomy site. 38 The evidence in the literature suggests that if rhBMP-2 reaches a raw bone surface such as a laminectomy site or a decompressed neural foramen in sufficient concentration, new bone will form and may result in restenosis. Leakage of rhBMP-2 beyond the fusion area may lead to fusion of adjacent levels. Therefore, the key steps for safe rhBMP-2 use are careful placement away from raw decompressed areas and retention of the rhBMP-2 within the fusion area by the carrier used.
It is well established that BMPs play a role in the regulation of coupled osteoblastic and osteoclastic activity.
30,33
It is possible that large doses of BMP may lead to localized areas of bone resorption. 57 This is not desirable in spinal fusion, and strategies to prevent this include careful con- Several studies have reported adverse local events associated with the use of rhBMP-2. Facial edema, oral erythema, pain, and rhinitis have been reported in patients who received rhBMP-2 for maxillary floor augmentation. 8 The use of higher than recommended doses of rhBMP-2 has been known to cause hematoma, dysphagia, and excessive edema after anterior cervical fusion. 49, 52 This may be due to the enhancement by rhBMP-2 of the initial inflammatory response that is seen during bone graft incorporation. 35 This same enhanced inflammatory response may produce a hyperinflammatory response causing wound problems, allergic reactions, or other complications. 24 
Risk-Benefit Balance
At the present time, the risk-benefit balance of BMP use during routine spinal fusion surgery is undetermined. Moreover, the scarcity of BMP studies in the pediatric age group makes the endeavor to establish clinical indications for BMP use in spine fusion surgery in children even more daunting. The average cost of hospitalization for those who received BMP and for those who did not was $58,653.70 and $53,420.50, respectively. The cost difference between these groups reached statistical significance (p < 0.001); the incremental difference is < 10%. Our finding has implications for the commonly held belief that BMP use is cost prohibitive.
Limitations of the Study
Our study was limited by the nature of the KID, which was designed to collect only discharge information from inpatient hospital admissions. Readmissions to the hospital are not linked by patient; thus clinical follow-up is unfortunately not available. We were not able to identify all specific operative indications. To our knowledge, the accuracy and consistency of the ICD-9-CM codes used to identify our study subjects' diagnoses and procedures have not been validated by independent chart review in this pediatric population. We have based our work on published methodologies used by multiple groups where available, 31,61 although inaccuracy of coding is an unquantified and notable limitation. Furthermore, we were not able to identify specific types or doses of BMP used; we assumed that rhBMP-2 was used in the majority of cases. A distinction between local autograft versus autograft from more remote donor sites could not be identified, and therefore it was not possible to determine how BMP influenced the harvest of autograft from donor sites such as the rib and iliac crest in children. Data on costs are reported by KID as a representative of total inpatient costs, and are taken as a research tool. Thus caution should be used in interpreting numbers as precise markers of financial exchange for individual cases. Most importantly, the administrative database provides a limited cross-sectional perspective and does not allow longitudinal patient follow-up.
Conclusions
Despite the limitations of our study, analysis of the KID allowed us to identify and report nationwide patterns of BMP use in pediatric occipitocervical, cervical, thoracic, lumbar, and sacral spine fusions. Additionally, we identified patient-related (older age, private insurance, and diagnosis of Scheuermann kyphosis or spondylolisthesis); hospital-related (nonchildren's hospital and Midwest location); and procedure-related factors (posterior occipitocervical and anterior lumbar approaches, shortand mid-length segment fusion, and redo surgery for failed fusion) that were associated with increased BMP use. More studies are needed to classify clinical indications for BMP use in pediatric spine surgery. 
